A Randomized,Open-label Dose-discovery Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency
Status:
Recruiting
Trial end date:
2026-01-05
Target enrollment:
Participant gender:
Summary
This study was a single-center,open-label,randomized,dose-exploring prospective
study.Patients with granulocytotic aplastic anemia who received cytokine treatment with
PEG-rhG-CSF or rhG-CSF were enrolled.Clinical demographic data,disease characteristics of
aplastic anemia,clinical diagnosis and treatment,laboratory data and adverse events were
collected to explore the dose and safety of PEG-rhG-CSF and rhG-CSF in patients with severe
aplastic anemia.